• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Oct 8:15:1483720.
doi: 10.3389/fimmu.2024.1483720. eCollection 2024. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice

Yaxin Di[SUP] 1 2 [/SUP], Chenchao Zhang[SUP] 3 [/SUP], Zilin Ren[SUP] 2 [/SUP], Renyue Jiang[SUP] 3 [/SUP], Jiafeng Tang[SUP] 4 [/SUP], Songhui Yang[SUP] 2 [/SUP], Ziliang Wang[SUP] 5 [/SUP], Tong Yu[SUP] 5 [/SUP], Tong Zhang[SUP] 6 [/SUP], Ziping Yu[SUP] 5 [/SUP], Zhiqiang Xu[SUP] 3 [/SUP], Xinyu Zhuang[SUP] 2 [/SUP], Ningyi Jin[SUP] 1 2 7 [/SUP], Mingyao Tian[SUP] 2 [/SUP]



Affiliations
Abstract

Introduction: The influenza virus is recognized as the primary cause of human respiratory diseases, with the current influenza vaccine primarily offering strain-specific immunity and limited protection against drifting strains. Considering this, the development of a broad-spectrum influenza vaccine capable of inducing effective immunity is considered the future direction in combating influenza.
Methods: The present study proposes a novel mRNA-based multi-epitope influenza vaccine, which combines three conserved antigens derived from the influenza A virus. The antigens consist of M2 ion channel's extracellular domain (M2e), the conserved epitope of located in HA2 of hemagglutinin (H1, H3, B), and HA1 of hemagglutinin. At the same time, trimeric sequences and ferritin were conjugated separately to investigate the immune effects of antigen multivalent presentation.
Results: Immunization studies conducted on C57BL/6 mice with these vaccines revealed that they can elicit both humoral immunity and CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell responses, which collectively contribute to enhancing cross-protective effects. The virus challenge results showed that vaccinated groups had significantly reduced lung damage, lower viral loads in the lungs, nasal turbinates, and trachea, as well as decreased levels of pro-inflammatory cytokines.
Conclusion: These findings clearly demonstrate the wide range of protective effects provided by these vaccines against H1N1 and B influenza viruses. The present finding highlights the potential of mRNA-based influenza vaccines encoding conserved proteins as a promising strategy for eliciting broad-spectrum protective humoral and cellular immunity against H1N1 and B influenza viruses.

Keywords: immunogenicity; influenza virus; mRNA vaccines; multivalent epitopes; nanoparticle.

 
Back
Top Bottom